Bulk Manufacturer of Controlled Substances Application: Patheon Pharmaceuticals, Inc., 15632 [2015-06733]
Download as PDF
<![CDATA[
15632
Federal Register / Vol. 80, No. 56 / Tuesday, March 24, 2015 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
[Docket No. DEA–392]
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Penick
Corporation
Bulk Manufacturer of Controlled
Substances Application: Patheon
Pharmaceuticals, Inc.
ACTION:
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class and applicants
therefore may file written comments or
objections to the issuance of the
proposed registration in accordance
with 21 CFR 1301.33(a) on or before
May 26, 2015.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on
December 11, 2014, Patheon
Pharmaceuticals, Inc., 2110 E. Galbraith
Road, Cincinnati, Ohio 45237 applied to
be registered as a bulk manufacturer of
gamma hydroxybutyric acid (2010), a
basic class of nonnarcotic controlled
substance in schedule I.
The company plans to manufacture
the listed controlled substance for
distribution to its customers.
mstockstill on DSK4VPTVN1PROD with NOTICES
Dated: March 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–06733 Filed 3–23–15; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
01:09 Mar 24, 2015
Jkt 235001
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.33(a) on
or before May 26, 2015.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152. Request for hearings should be
sent to: Drug Enforcement
Administration, Attention: Hearing
Clerk/LJ, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Deputy Assistant
Administrator of the DEA Office of
Diversion Control (‘‘Deputy Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart, R.
In accordance with 21 CFR
1301.33(a), this is notice that on
February 26, 2014, Penick Corporation,
33 Industrial Park Road, Pennsville,
New Jersey 08070, applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
DATES:
DATES:
SUPPLEMENTARY INFORMATION:
Notice of application.
Controlled substance
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Schedule
II
II
II
II
II
II
II
II
II
Controlled substance
Thebaine (9333) ...........................
Opium tincture (9630) ..................
Oxymorphone (9652) ...................
Schedule
II
II
II
The company plans to manufacture
the above-listed controlled substances
as bulk controlled substance
intermediates for distribution to its
customers.
Dated: March 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015–06734 Filed 3–23–15; 8:45 am]
BILLING CODE 4410–09–P
LIBRARY OF CONGRESS
Copyright Royalty Board
[Docket No. 14–CRB–0006 DART SR (CO/
FA) 2013]
Distribution of the 2013 Digital Audio
Recording Technology Royalty Funds
Copyright Royalty Board,
Library of Congress.
ACTION: Notice announcing
commencement of proceeding with
request for Petitions to Participate and
comments on intention to conduct
paper proceeding.
AGENCY:
The Copyright Royalty Board
is announcing the commencement of a
proceeding to determine the distribution
of the digital audio recording
technology royalty fees in the 2013
Sound Recordings Fund (Copyright
Owners and Featured Recording Artists
Subfunds). The Board is also
announcing the date by which a party
who wishes to participate in this
proceeding must file its Petition to
Participate and the accompanying $150
filing fee, if applicable. Finally, the
Board is announcing the Copyright
Royalty Judges’ intention to conduct a
paper proceeding.
DATES: Petitions to Participate,
comments on the intention to conduct a
paper proceeding, and applicable filing
fee are due no later than April 23, 2015.
ADDRESSES: An original, five copies, and
an electronic copy in Portable
Document Format (PDF) on a CD of the
Petition to Participate, along with the
$150 filing fee, if applicable, may be
delivered to the Copyright Royalty
Board by either mail or hand delivery.
Petitions to Participate and the $150
filing fee may not be delivered by an
overnight delivery service other than the
U.S. Postal Service Express Mail. If by
mail (including overnight delivery),
SUMMARY:
E:\FR\FM\24MRN1.SGM
24MRN1
]]>Agencies
[Federal Register Volume 80, Number 56 (Tuesday, March 24, 2015)]
[Notices]
[Page 15632]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06733]
[[Page 15632]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Patheon
Pharmaceuticals, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class and
applicants therefore may file written comments or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.33(a) on or before May 26, 2015.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152. Request for
hearings should be sent to: Drug Enforcement Administration, Attention:
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Deputy Assistant Administrator of the DEA Office of Diversion
Control (``Deputy Assistant Administrator'') pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
December 11, 2014, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith
Road, Cincinnati, Ohio 45237 applied to be registered as a bulk
manufacturer of gamma hydroxybutyric acid (2010), a basic class of
nonnarcotic controlled substance in schedule I.
The company plans to manufacture the listed controlled substance
for distribution to its customers.
Dated: March 9, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-06733 Filed 3-23-15; 8:45 am]
BILLING CODE 4410-09-P
